Hamad Alshetaiwi

Dr. Hamad Alshetaiwi

orcid

Research Focus & Metrics

Representative Publications

View All Publications
21 February 2020 in Science Immunology
Verified
Journal Article
Closed access
PDF file
HAHamad Alshetaiwi
Hamad Alshetaiwi
NPNicholas Pervolarakis
Nicholas Pervolarakis
LMLaura Lynn McIntyre
Laura Lynn McIntyre
DMDennis Ma
Dennis Ma
QNQuy Nguyen
Quy Nguyen
KKKai Kessenbrock
Kai Kessenbrock
Alshetaiwi et al. identify CD84 to be a robust MSDC-specific cell surface marker in breast cancers.

28 May 2024 in Nature Immunology
Verified
Journal Article
Closed access
PDF file
BFBridget M. Fortin
Bridget M. Fortin
SPShannon M. Pfeiffer
Shannon M. Pfeiffer
JIJacob Insua-Rodríguez
Jacob Insua-Rodríguez
HAHamad Alshetaiwi
Hamad Alshetaiwi
AMAlexander Moshensky
Alexander Moshensky
SMSelma Masri
Selma Masri

13 March 2023 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
KNKevin Nee
Kevin Nee
DMDennis Ma
Dennis Ma
QNQuy H. Nguyen
Quy H. Nguyen
MPMaren Pein
Maren Pein
NPNicholas Pervolarakis
Nicholas Pervolarakis
KKKai Kessenbrock
Kai Kessenbrock

21 March 2025 in Acta Diabetologica
Verified
Journal Article
Closed access
PDF file
AKAzharuddin Sajid Syed Khaja
Azharuddin Sajid Syed Khaja
NBNaif K BinSaleh
Naif K BinSaleh
Husam QanashHusam Qanash
Husam Qanash
HAHamad Alshetaiwi
Hamad Alshetaiwi
IGIbrahim Abdelmageed Mohamed Ginawi
Ibrahim Abdelmageed Mohamed Ginawi
MSMohd Saleem
Mohd Saleem

3 February 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
JIJacob Insua-Rodríguez
Jacob Insua-Rodríguez
PNPascal Naef
Pascal Naef
HSHannah Savage
Hannah Savage
IAIsam Adam
Isam Adam
SCSung Kook Chun
Sung Kook Chun
DLDevon Ann Lawson
Devon Ann Lawson
Systemic, multi-organ metastasis is the primary cause of breast cancer mortality, yet the biological mechanisms that allow disseminated tumor cells to simultaneously colonize physiologically diverse tissues remain poorly understood. Current paradigms focus on organ-specific tropism, largely overlooking the potential for systemic, conserved and synchronized programs that facilitate widespread colonization. Here, we present a high-resolution, multi-organ atlas of metastatic ecosystems and their niches using a synchronous model of brain, lung, liver, and bone metastasis combined with in vivo proximal niche labeling and single-cell RNA sequencing. We identify a remarkably conserved proximal niche program defined by the accumulation of CD74 + lipid-associated, metastasis-associated macrophages (LA-MAMs) across all metastatic sites. CD74 + LA-MAMs are characterized by a unique metabolic-immune signature and drive T cell suppression. We show that the cytokine Macrophage Migration Inhibitory Factor (MIF), secreted by metastatic cells, acts as the universal paracrine mediator that instructs the LA-MAM phenotype via the CD74 receptor. Interference of the MIF-CD74 axis effectively disrupts the LA-MAM niche, mitigates T cell exhaustion, and reduces metastatic burden across all organs. Analysis of a 100-patient cohort of metastasis samples from different sites confirms that the MIF-CD74 axis is a hallmark of human multi-organ colonization and independently predicts poor post-metastasis survival. Our findings define a synchronized and systemic metastatic niche that can be targeted, providing a mechanistic rationale for neutralizing the MIF-CD74 axis to treat polymetastatic breast cancer.

14 November 2026 in Diagnostics
Verified
Journal Article
Open access
PDF file
KSKamal (short of Kamaleldin) Said
Kamal (short of Kamaleldin) Said
AAAhmed Alsolami
Ahmed Alsolami
RARuba Mustafa Elsaid Ahmed
Ruba Mustafa Elsaid Ahmed
KAKhalid F Alshammari
Khalid F Alshammari
HAHamad Alshetaiwi
Hamad Alshetaiwi
NANorah Kheder Alharbi
Norah Kheder Alharbi
Background: Timely integrated diagnostic microbiology combines automated identification and antimicrobial susceptibility testing (AST) with assay-specific molecular confirmation. This allows final resistance classifications to be interpreted within one clinical workflow. The novelty of this study is the integration of these complementary diagnostic outputs with organism identity, specimen source, care setting, and available host context across a mixed-pathogen tertiary-care cohort. We characterized the distribution of major clinical priority-pathogen resistance profiles and examined clinical factors associated with high-priority resistances. Methods: This retrospective cross-sectional laboratory-based study included 847 non-duplicate clinical isolates recovered during routine care from a pre-established surveillance cohort at King Salman Specialist tertiary-care hospital in Saudi Arabia from July 2025 to July 2026. Automated organism identification/AST was combined with assay-specific GeneXpert molecular confirmation where applicable. GeneXpert SA Nasal Complete was used for Staphylococcus aureus/MRSA confirmation and Xpert Carba-R for relevant carbapenemase targets; organisms outside these target panels, including Streptococcus pyogenes and Candida spp., were characterized by routine culture and automated identification. Carbapenem resistance was defined by imipenem and/or meropenem resistance and reported as carbapenem-resistant Enterobacterales (CRE) for Klebsiella pneumoniae and Escherichia coli, carbapenem-resistant Pseudomonas aeruginosa (CRPA), and carbapenem-resistant Acinetobacter baumannii (CRAB). Methicillin-resistant Staphylococcus aureus (MRSA) was classified by cefoxitin resistance with concordant GeneXpert confirmation. Exploratory multivariable logistic regression assessed clinical factors associated with CRE and MRSA detection. Results: Gram-negative organisms accounted for 546 isolates (64.5%), Gram-positive organisms accounted for 281 (33.2%), and fungi accounted for 20 (2.4%). Klebsiella pneumoniae was most frequent (176/847; 20.8%), followed by Staphylococcus aureus (169/847; 20.0%) and Escherichia coli (156/847; 18.4%). Priority resistance was highest in Acinetobacter baumannii, with CRAB in 73/74 isolates (98.6%), followed by CRPA in 38/83 P. aeruginosa (45.8%), MRSA in 68/164 S. aureus (41.5%), CRE in 57/176 K. pneumoniae (32.4%), and CRE in 10/156 E. coli (6.4%). In the complete-case CRE model (n = 246; 38 events), K. pneumoniae had higher adjusted odds of CRE than E. coli (aOR 3.91, 95% CI 1.74–9.73; p = 0.002). In the MRSA model (n = 160; 68 events), non-urinary specimens (aOR 3.31, 95% CI 1.21–10.16; p = 0.025) and recorded comorbidity (aOR 3.40, 95% CI 1.26–9.64; p = 0.017) were independently associated with MRSA detection. Conclusions: The integrated diagnostic workflow revealed marked organism-specific differences in resistance, led by a very high CRAB burden and substantial CRPA, MRSA, and K. pneumoniae CRE. Interpreting the final laboratory classification together with organism identity, specimen source, and care setting provides a practical framework for focused diagnostic reporting, antimicrobial stewardship, and infection-control prioritization in tertiary care.